Pulmonary tuberculosis screening in anti-retroviral treated adults living with HIV in Kenya.
AIDS-Related Opportunistic Infections
/ diagnosis
Adult
Anti-Retroviral Agents
/ therapeutic use
Antitubercular Agents
/ therapeutic use
Female
Humans
Isoniazid
/ therapeutic use
Kenya
/ epidemiology
Male
Mass Screening
/ methods
Middle Aged
Prevalence
Prospective Studies
Tuberculosis, Pulmonary
/ diagnosis
AIDS-related opportunistic infections epidemiology
Diagnostic tests
Latent Tuberculosis
Prevalence
Tuberculosis
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
25 Feb 2021
25 Feb 2021
Historique:
received:
07
11
2020
accepted:
11
02
2021
entrez:
26
2
2021
pubmed:
27
2
2021
medline:
20
3
2021
Statut:
epublish
Résumé
People living with HIV (PLHIV) who reside in high tuberculosis burden settings remain at risk for tuberculosis disease despite treatment with anti-retroviral therapy and isoniazid preventive therapy (IPT). The performance of the World Health Organization (WHO) symptom screen for tuberculosis in PLHIV receiving anti-retroviral therapy is sub-optimal and alternative screening strategies are needed. We enrolled HIV-positive adults into a prospective study in western Kenya. Individuals who were IPT-naïve or had completed IPT > 6 months prior to enrollment were eligible. We evaluated tuberculosis prevalence overall and by IPT status. We assessed the accuracy of the WHO symptom screen, GeneXpert MTB/RIF (Xpert), and candidate biomarkers including C-reactive protein (CRP), hemoglobin, erythrocyte sedimentation rate (ESR), and monocyte-to-lymphocyte ratio for identifying pulmonary tuberculosis. Some participants were evaluated at 6 months post-enrollment for tuberculosis. The study included 383 PLHIV, of whom > 99% were on antiretrovirals and 88% had received IPT, completed a median of 1.1 years (IQR 0.8-1.55) prior to enrollment. The prevalence of pulmonary tuberculosis at enrollment was 1.3% (n = 5, 95% CI 0.4-3.0%): 4.3% (0.5-14.5%) among IPT-naïve and 0.9% (0.2-2.6%) among IPT-treated participants. The sensitivity of the WHO symptom screen was 0% (0-52%) and specificity 87% (83-90%). Xpert and candidate biomarkers had poor to moderate sensitivity; the most accurate biomarker was CRP ≥ 3.3 mg/L (sensitivity 80% (28-100) and specificity 72% (67-77)). Six months after enrollment, the incidence rate of pulmonary tuberculosis following IPT completion was 0.84 per 100 person-years (95% CI, 0.31-2.23). In Kenyan PLHIV treated with IPT, tuberculosis prevalence was low at a median of 1.4 years after IPT completion. WHO symptoms screening, Xpert, and candidate biomarkers were insensitive for identifying pulmonary tuberculosis in antiretroviral-treated PLHIV.
Sections du résumé
BACKGROUND
BACKGROUND
People living with HIV (PLHIV) who reside in high tuberculosis burden settings remain at risk for tuberculosis disease despite treatment with anti-retroviral therapy and isoniazid preventive therapy (IPT). The performance of the World Health Organization (WHO) symptom screen for tuberculosis in PLHIV receiving anti-retroviral therapy is sub-optimal and alternative screening strategies are needed.
METHODS
METHODS
We enrolled HIV-positive adults into a prospective study in western Kenya. Individuals who were IPT-naïve or had completed IPT > 6 months prior to enrollment were eligible. We evaluated tuberculosis prevalence overall and by IPT status. We assessed the accuracy of the WHO symptom screen, GeneXpert MTB/RIF (Xpert), and candidate biomarkers including C-reactive protein (CRP), hemoglobin, erythrocyte sedimentation rate (ESR), and monocyte-to-lymphocyte ratio for identifying pulmonary tuberculosis. Some participants were evaluated at 6 months post-enrollment for tuberculosis.
RESULTS
RESULTS
The study included 383 PLHIV, of whom > 99% were on antiretrovirals and 88% had received IPT, completed a median of 1.1 years (IQR 0.8-1.55) prior to enrollment. The prevalence of pulmonary tuberculosis at enrollment was 1.3% (n = 5, 95% CI 0.4-3.0%): 4.3% (0.5-14.5%) among IPT-naïve and 0.9% (0.2-2.6%) among IPT-treated participants. The sensitivity of the WHO symptom screen was 0% (0-52%) and specificity 87% (83-90%). Xpert and candidate biomarkers had poor to moderate sensitivity; the most accurate biomarker was CRP ≥ 3.3 mg/L (sensitivity 80% (28-100) and specificity 72% (67-77)). Six months after enrollment, the incidence rate of pulmonary tuberculosis following IPT completion was 0.84 per 100 person-years (95% CI, 0.31-2.23).
CONCLUSIONS
CONCLUSIONS
In Kenyan PLHIV treated with IPT, tuberculosis prevalence was low at a median of 1.4 years after IPT completion. WHO symptoms screening, Xpert, and candidate biomarkers were insensitive for identifying pulmonary tuberculosis in antiretroviral-treated PLHIV.
Identifiants
pubmed: 33632173
doi: 10.1186/s12879-021-05916-z
pii: 10.1186/s12879-021-05916-z
pmc: PMC7908695
doi:
Substances chimiques
Anti-Retroviral Agents
0
Antitubercular Agents
0
Isoniazid
V83O1VOZ8L
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
218Subventions
Organisme : NIAID NIH HHS
ID : K23 AI120793
Pays : United States
Références
Lancet Glob Health. 2017 Nov;5(11):e1080-e1089
pubmed: 29025631
J Biomed Inform. 2014 Apr;48:193-204
pubmed: 24582925
Emerg Infect Dis. 2006 May;12(5):744-51
pubmed: 16704830
Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 2):S221-47
pubmed: 10764341
Lancet HIV. 2018 Sep;5(9):e515-e523
pubmed: 30139576
Lancet. 2014 Aug 23;384(9944):682-90
pubmed: 24835842
Biopreserv Biobank. 2012 Feb;10(1):4-11
pubmed: 24849748
Lancet. 2011 May 7;377(9777):1588-98
pubmed: 21492926
J Acquir Immune Defic Syndr. 2010 May 1;54(1):71-7
pubmed: 19934764
Int J Tuberc Lung Dis. 2003 Aug;7(8):758-63
pubmed: 12921152
PLoS One. 2018 Jan 31;13(1):e0192030
pubmed: 29385208
N Engl J Med. 2015 Aug 27;373(9):808-22
pubmed: 26193126
J Clin Epidemiol. 1996 Dec;49(12):1373-9
pubmed: 8970487
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Cochrane Database Syst Rev. 2014 Jan 21;(1):CD009593
pubmed: 24448973
PLoS One. 2018 Dec 26;13(12):e0209098
pubmed: 30586448
Lancet HIV. 2016 Aug;3(8):e361-e387
pubmed: 27470028
Lancet Infect Dis. 2016 Nov;16(11):1269-1278
pubmed: 27522233
AIDS. 2018 Aug 24;32(13):1811-1820
pubmed: 29847333
PLoS One. 2017 Feb 16;12(2):e0171358
pubmed: 28208160
AIDS. 2014 Jun 19;28(10):1463-72
pubmed: 24681417
Bull World Health Organ. 1955;12(1-2):189-96
pubmed: 14351974
PLoS One. 2012;7(12):e47400
pubmed: 23251327
J Acquir Immune Defic Syndr. 2014 May 1;66(1):33-40
pubmed: 24346639
AIDS. 2010 Apr 24;24(7):1051-5
pubmed: 20299958
Cochrane Database Syst Rev. 2019 Jun 07;6:CD009593
pubmed: 31173647
PLoS One. 2016 May 11;11(5):e0154142
pubmed: 27167381
Am J Epidemiol. 2006 Apr 1;163(7):670-5
pubmed: 16410346
AIDS. 2015 Jan 28;29(3):351-9
pubmed: 25686683
AIDS Care. 2012;24(11):1448-52
pubmed: 22670758
J Acquir Immune Defic Syndr. 2016 Feb 1;71(2):219-27
pubmed: 26334736
Int J Tuberc Lung Dis. 2013 Aug;17(8):1036-42
pubmed: 23827027
PLoS Med. 2011 Jan 18;8(1):e1000391
pubmed: 21267059
Int J Tuberc Lung Dis. 2017 Sep 01;21(9):1013-1019
pubmed: 28826451
Am J Respir Crit Care Med. 2011 Nov 1;184(9):1076-84
pubmed: 21836139
Lancet Infect Dis. 2017 Dec;17(12):1285-1292
pubmed: 28847636
Int J Tuberc Lung Dis. 2018 Jun 1;22(6):596-605
pubmed: 29862942
AIDS. 2016 May 15;30(8):1279-86
pubmed: 26950316
PLoS One. 2016 Dec 9;11(12):e0167685
pubmed: 27936146
AIDS. 2016 Jun 19;30(10):1607-15
pubmed: 27243774
PLoS One. 2018 Jan 11;13(1):e0190659
pubmed: 29324811
Clin Infect Dis. 2012 Dec;55(12):1698-706
pubmed: 22955441
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Int J Tuberc Lung Dis. 2013 Feb;17(2):178-85
pubmed: 23317952
N Engl J Med. 2011 Jul 7;365(1):11-20
pubmed: 21732833